Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265910 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
A Phase 4 study of Allergic Conjunctivitis, sponsored by Andover Research Eye Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT05265910 is a Phase 4 study of Allergic Conjunctivitis that has completed, run by Andover Research Eye Institute. The registered enrollment target is 58 participants, below the 132-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05265910, a Phase 4 study of Allergic Conjunctivitis, has completed, sponsored by Andover Research Eye Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG olopatadine hydrochloride ophthalmic solution 0.7%
- DRUG loratadine 10 mg
- DRUG Tears Naturale
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2022-04-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05265910
The ClinicalTrials.gov registry entry for NCT05265910 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (56% lower). The listed sponsor is Andover Research Eye Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05265910 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05265910 about?
NCT05265910 is a clinical study titled "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis". This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for asses...
What is the current status of trial NCT05265910?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2021-12-14. Estimated completion is 2022-04-23.
What conditions does trial NCT05265910 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT05265910?
The interventions under investigation include: Placebo (DRUG), olopatadine hydrochloride ophthalmic solution 0.7% (DRUG), loratadine 10 mg (DRUG), Tears Naturale (DRUG).
Who is sponsoring clinical trial NCT05265910?
This trial is sponsored by Andover Research Eye Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05265910 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Alcon's Ocular Image Quantification System
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.